Q-omics provides the consensus-scored MTM1 profile across patient tissues and cancer cell-line models. MTM1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MTM1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, MTM1 protein abundance shows 22,781 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, COAD, and LUAD as cancer lineages where MTM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTM1 survival associations across molecular data types. MTM1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTM1 RNA expression–survival associations across cancer types. High MTM1 expression shows favorable associations in KIRC, ACC, SKCM, SARC, COAD and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MTM1 RNA expression.
This table summarizes MTM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTM1 shows lower tumor expression in COAD, LUAD, LUSC, READ and UCEC and higher tumor expression in HNSC. The COAD box plot shows higher MTM1 RNA expression in normal versus tumor tissue (log2 FC = −1.359, t-test p < 0.001).
This table shows molecular features associated with MTM1 in patient tissues and cancer cell lines. In patient samples, MTM1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MTM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
